Table 3.
Correlation between lymphocyte subpopulation changes and chemoradiotherapy characteristics
| Variables | Chemo-regimen (EP vs EC) | Chemo-cycle (≤ 4 vs > 4) | RT dose/fraction (1.5 vs 2.0 Gy) | RT frequency (Qd vs Bid) | CRT method (concurrent vs sequential) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| z | p | z | p | z | p | z | p | z | p | |
| Δ CD3+ T cell | − .932 | .351 | − .728 | .466 | − .043 | .966 | − .082 | .935 | − .582 | .560 |
| Δ CD3+CD4+ T cell | − .921 | .357 | − .359 | .720 | − 1.623 | .105 | − 1.311 | .190 | − .291 | .771 |
| Δ CD4+CD45RA+ T cell | − .238 | .812 | − .815 | .415 | − .363 | .716 | − .088 | .929 | − .251 | .802 |
| Δ CD3+CD8+ T cell | − .314 | .753 | − .828 | .408 | − 1.099 | .363 | − 1.091 | .275 | − .649 | .516 |
| Δ CD8+CD38+ T cell | − 1.985 | .047* | − .334 | .738 | − .207 | .836 | − .044 | .965 | − .146 | .884 |
| Δ CD4/CD8 ratio | − .580 | .562 | − .837 | .403 | − 1.352 | .176 | − 1.284 | .199 | − .636 | .525 |
| Δ CD19+ B cell | − 1.763 | .083 | − .434 | .664 | − .559 | .576 | − .185 | .853 | − .352 | .000** |
| Δ CD3−CD56+ NK cell | − .464 | .643 | − .762 | .446 | − .396 | .692 | − .227 | .821 | − 1.355 | .175 |
| Δ CD3+CD56+ NKT cell | − .743 | .458 | − .1609 | .108 | − .070 | − 1.221 | − .822 | .411 | − 1.001 | .317 |
Chemo-regimen Chemotherapy regimen; Chemo-cycle Chemotherapy cycle; RT Radiotherapy; CRT Chemoradiotherapy; EP Cisplatin plus Etoposide; EC Carboplatin plus Etoposide; Qd Once daily; Bid Twice daily. *p ≤ 0.05; **p ≤ 0.001